Goodwin Advises Ouro Medicines on Its $120 Million Launch and In-License for Keymed's Novel T-Cell Engager
January 11, 2025
January 11, 2025
BOSTON, Massachusetts, Jan. 11 -- Goodwin, a law firm, issued the following news release:
The Life Sciences team advised Ouro Medicines on its launch with $120 million in funding. The company was founded by Monograph Capital in partnership with GSK plc. The Series A was co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners, with participation from Monograph Capital, GSK, UPMC Enterprises, Boyu/Zoo Capital, LongRiver Investments, and other unnamed investors. Ouro . . .
The Life Sciences team advised Ouro Medicines on its launch with $120 million in funding. The company was founded by Monograph Capital in partnership with GSK plc. The Series A was co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners, with participation from Monograph Capital, GSK, UPMC Enterprises, Boyu/Zoo Capital, LongRiver Investments, and other unnamed investors. Ouro . . .